Dr. Julian Reed Davis, MD

Dr. Davis practices at UCLA Medical Plaza in Santa Barbara, California.

Dr. Davis' NPI, 1801159967, was assigned on June 22, 2012. Dr. Davis graduated from Royal College of Surgeons Ireland in 2012. Dr. Davis holds California license A136956.

Dr. Davis' primary practice is UCLA Medical Plaza, at 309 W Quinto St, Santa Barbara, CA 93105 in Santa Barbara County. The practice phone is (310) 794-1276.

Dr. Davis' primary practice is UCLA Medical Plaza in Santa Barbara, California. Dr. Davis is also affiliated with Santa Barbara Cottage Hospital. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Davis to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Davis practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Davis' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Davis is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Davis' licenses on file in 2 states: California and Pennsylvania.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), fluid and electrolyte imbalances and immune deficiency disease among the conditions Dr. Davis treats.

CMS data shows 118,130 Medicare services from Dr. Davis across 41 procedure codes in 2024, for 593 Medicare patients. Medicare paid $2,732,449 for them.

CMS counts 593 Medicare patients who saw Dr. Davis in 2024. The largest group is 75 to 84, with 270 patients. 74% of them have high cholesterol, and 66% have high blood pressure. 10% are also on Medicaid. Their average risk score is 1.99, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Davis' median patient age at 73, with 49% women.

In 2024, Dr. Davis wrote 532 Medicare Part D claims for 119 patients. 74% of them were for generic drugs. CMS names the drug for 356 of them, across 13 drugs with 11 or more claims each, at $1,879,132 in total drug cost. In 2023, CMS named 265 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Davis for performance year 2024, reported as part of a group. Dr. Davis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Davis as offering telehealth.

Dmand AI links 4 papers to Dr. Davis, published from 2018 to 2024. The most frequent topics are Antineoplastic Agents. Dr. Davis' most frequent co-authors are Brian Andrew Jonas, MD, PhD, David J. Benjamin, MD and Sucharita Boddu, MD.

Dmand AI links Dr. Davis to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms and Prostatic Diseases. Open Payments lists research payments to Dr. Davis that name 1 trial.

CMS Open Payments shows 125 general payments to Dr. Davis from 37 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 79% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $1,166. It also lists 1 research payment totaling $4,360 in 2020, naming 1 clinical trial.

Dr. Davis graduated from Royal College of Surgeons Ireland in 2012. Dr. Davis is a member of ACP, ASCO and ASH.

Dr. Davis is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.